Arbutus Biopharma
Canadian Bio Tech Company
ABUS Nasdaq
ISIN CA03879J1003 SEC CIK 1447028
Follow Arbutus Biopharma
Weekly email: filings, results
Revenue, last quarter
$299K
−43.5% vs same quarter last year
Net income
$59.1M
+863.6% vs same quarter last year
EPS, diluted
$0.30
+850% vs same quarter last year
Operating cash flow
$239.8M
+4222.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $14.1M | −$33.5M |
| FY24 | $6.2M | −$69.9M |
| FY23 | $18.1M | −$72.8M |
| FY22 | $39M | −$69.5M |
| FY21 | $11M | −$76.2M |
| FY20 | $6.9M | −$63.7M |
| FY19 | $6M | −$153.7M |
| FY18 | $5.9M | −$57.1M |
| FY17 | $10.7M | −$84.4M |
| FY16 | $1.5M | −$384.2M |
| FY15 | $23.3M | −$62.7M |
| FY14 | $15M | −$38.8M |
| FY13 | $15.5M | −$14.1M |
| FY12 | $14.1M | $29.6M |
| FY11 | $16.8M | −$10.1M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −271% | −237.9% |
| FY24 | −1236.7% | −1133% |
| FY23 | −430.5% | −401.6% |
| FY22 | −167.8% | −178% |
| FY21 | −669.1% | −693.9% |
| FY20 | −836.1% | −922% |
| FY19 | −2394% | −2557.4% |
| FY18 | −1510.2% | −959.8% |
| FY17 | −1036.7% | −788.9% |
| FY16 | −32973.8% | −25765.5% |
| FY15 | −446.5% | −269.5% |
| FY14 | −223.6% | −259.7% |
| FY13 | −78.6% | −90.9% |
| FY12 | −91.8% | 209.9% |
| FY11 | −63.6% | −60% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$39.6M |
| FY24 | −$65M |
| FY23 | −$86.9M |
| FY22 | −$35.9M |
| FY21 | −$68.3M |
| FY20 | −$51.7M |
| FY19 | −$71.6M |
| FY18 | −$69M |
| FY17 | −$55.9M |
| FY16 | −$61.9M |
| FY15 | −$58.7M |
| FY14 | −$13.5M |
| FY13 | −$7.5M |
| FY12 | $32.9M |
| FY11 | −$7.9M |
- Arbutus Biopharma
- Healthcare median
Show the numbers
| Year | Arbutus Biopharma | Healthcare median |
|---|---|---|
| FY25 | −237.9% | −30.6% |
| FY24 | −1133% | −47% |
| FY23 | −401.6% | −58% |
| FY22 | −178% | −80.4% |
| FY21 | −693.9% | −71.9% |
| FY20 | −922% | −62.2% |
| FY19 | −2557.4% | −46.3% |
| FY18 | −959.8% | −49.6% |
| FY17 | −788.9% | −45.9% |
| FY16 | −25765.5% | −36% |
| FY15 | −269.5% | −38.4% |
| FY14 | −259.7% | −35.5% |
| FY13 | −90.9% | −37.1% |
| FY12 | 209.9% | −29.1% |
| FY11 | −60% | −27.9% |